Tema Heart & Health ETF $HRTS Shares Bought by CoreCap Advisors LLC

CoreCap Advisors LLC raised its holdings in shares of Tema Heart & Health ETF (NASDAQ:HRTS) by 25,280.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,776 shares of the company’s stock after acquiring an additional 51,572 shares during the period. CoreCap Advisors LLC owned approximately 3.30% of Tema Heart & Health ETF worth $1,602,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HRTS. JPMorgan Chase & Co. purchased a new position in shares of Tema Heart & Health ETF during the second quarter worth $63,000. Jane Street Group LLC grew its position in Tema Heart & Health ETF by 9.4% during the 2nd quarter. Jane Street Group LLC now owns 37,164 shares of the company’s stock worth $1,062,000 after purchasing an additional 3,202 shares during the period. Finally, Oliver Lagore Vanvalin Investment Group purchased a new position in shares of Tema Heart & Health ETF during the 2nd quarter valued at about $905,000.

Tema Heart & Health ETF Stock Down 1.3%

Shares of HRTS stock opened at $36.17 on Friday. Tema Heart & Health ETF has a 52-week low of $25.32 and a 52-week high of $36.63. The stock has a market cap of $56.06 million, a PE ratio of 22.06 and a beta of 0.97. The business has a 50-day simple moving average of $34.84 and a 200-day simple moving average of $31.63.

Tema Heart & Health ETF Announces Dividend

The business also recently disclosed a dividend, which was paid on Thursday, December 11th. Shareholders of record on Wednesday, December 10th were given a $0.4729 dividend. The ex-dividend date was Wednesday, December 10th.

Tema Heart & Health ETF Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.